Home › Compare › TRPTF vs ABBV
TRPTF yields 1157.74% · ABBV yields 3.06%● Live data
📍 TRPTF pulled ahead of the other in Year 1
Combined, TRPTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TRPTF + ABBV for your $10,000?
Tribe Property Technologies Inc., a property technology company, provides technology-enabled property management services. It operates through Software and Services, and Software Licensing Fees segments. The company engages in the tech-enabled management of condominium and residential communities through its condo-living software platform, and provision of support, community management platform, and related services to real estate developers, condominium and residential communities, and owners and residents through its deficiency management software. It offers its services under the Tribe, Tribe Management, Tribe Property Technologies, Tribe PropTech, Tribe Home, Tribe Rentals, Tribe Home Pro, Home Pro, Gateway, Gateway Property Management, bazinga, bazinga community, bazinga Build, Pendo, and Pendo Rental brand names. The company was formerly known as Cherry Street Capital Inc. and changed its name to Tribe Property Technologies Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Full TRPTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.